Arcturus Therapeutics Files 8-K

TL;DR

ARCT filed an 8-K, standard update, no major news.

AI Summary

Arcturus Therapeutics Holdings Inc. filed an 8-K on August 29, 2025, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing serves as a routine update for investors, confirming the company's adherence to SEC reporting standards without disclosing new material information.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not contain any new material information that would immediately impact the company's risk profile.

Key Players & Entities

• Arcturus Therapeutics Holdings Inc. (company) — Registrant
• August 29, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 10628 Science Center Drive, Suite 250, San Diego, California 92121 (address) — Principal Executive Offices
• (858) 900-2660 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share ARCT The NASDAQ Stock Mar

Filing Documents

• e664805_8k-arct.htm (8-K) — 26KB
• e664805_ex99-1.htm (EX-99.1) — 3KB
• image_001.jpg (GRAPHIC) — 27KB
• 0001193805-25-001247.txt ( ) — 231KB
• arct-20250829.xsd (EX-101.SCH) — 3KB
• arct-20250829_lab.xml (EX-101.LAB) — 33KB
• arct-20250829_pre.xml (EX-101.PRE) — 22KB
• e664805_8k-arct_htm.xml (XML) — 4KB

01

Item 7.01 Regulation FD Disclosure. On August 29, 2025, Meiji Holdings Co., Ltd. announced that its subsidiary, Meiji Seika Pharma Co., Ltd. (" Meiji "), announced today that it has received manufacturing and marketing approval in Japan for a new presentation of KOSTAIVE (ARCT-2301), a self-amplifying mRNA vaccine against COVID-19. The product targets the SARS-CoV-2 Omicron sub lineage JN.1 variant XEC. In non-clinical studies, it induced neutralizing antibodies not only against Omicron JN.1 and XEC, but also against LP.8.1 and the currently circulating variants XFG and NB.1.8.1. The formulation is supplied as a two-dose vial, with one vial per carton. As previously announced on April 11, 2023, Meiji entered into a distribution agreement with Seqirus, Inc. (" CSL Seqirus "), a part of CSL Limited, and one of the world's leading influenza vaccine providers, for the distribution and sales of Arcturus Therapeutics Holdings Inc.'s (the " Company " or " Arcturus ") self-amplifying mRNA vaccine candidate against COVID-19 in Japan. A copy of Meiji's press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information set forth in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchan g e Act "), or otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any sta

Financial Statements and Exhibits

Financial Statements and Exhibits . (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 29, 2025

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arcturus Therapeutics Holdings Inc. Date: August 29, 2025 By: /s/ Joseph E. Payne Name: Joseph E. Payne Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR